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A B S T R A C T
Purpose
To report on the long-term resultsof a randomized trial comparinga standarddose (400mg/d) versus ahigher
dose (800 mg/d) of imatinib in patients with metastatic or locally advanced GI stromal tumors (GISTs).
Patients and Methods
Eligible patients with advanced CD117-positive GIST from 56 institutions in 13 countries were
randomly assigned to receive either imatinib 400 mg or 800 mg daily. Patients on the 400-mg arm
were allowed to cross over to 800 mg upon progression.
Results
Between February 2001 and February 2002, 946 patients were accrued. Median age was 60 years
(range, 18 to 91 years). Median follow-up time was 10.9 years. Median progression-free survival times
were 1.7 and 2.0 years in the 400- and 800-mg arms, respectively (hazard ratio, 0.91;P= .18), andmedian
overall survival time was 3.9 years in both treatment arms. The estimated 10-year progression-free
survival rates were 9.5% and 9.2% for the 400- and 800-mg arms, respectively, and the estimated
10-year overall survival rates were 19.4% and 21.5%, respectively. At multivariable analysis, age
(, 60 years), performance status (0 v $ 1), size of the largest lesion (smaller), and KIT mutation
(exon 11) were signiﬁcant prognostic factors for the probability of surviving beyond 10 years.
Conclusion
This trial was carried out on a worldwide intergroup basis, at the beginning of the learning curve of
the use of imatinib, in a large population of patientswith advancedGIST.With a long follow-up, 6%of
patients are long-term progression free and 13% are survivors. Among clinical prognostic factors,
only performance status, KITmutation, and size of largest lesion predicted long-term outcome, likely
pointing to a lower burden of disease. Genomic and/or immune proﬁling could help understand long-
term survivorship. Addressing secondary resistance remains a therapeutic challenge.
J Clin Oncol 35. © 2017 by American Society of Clinical Oncology
INTRODUCTION
After the earliest informal reports of patients with
advanced GI stromal tumors (GISTs) responding
to the new agent imatinib, which was originally
developed to target BCR-ABL in chronic myeloid
leukemia, at the end of 2000, the decision was
made to launch two twin clinical trials in North
America and in Europe and Australia.1-3 The trials
were designed as randomized trials testing two
different dose levels of imatinib, 400 and 800 mg
daily.4,5 The aim was to optimize the dosing of
a drug that anecdotally was already known to be
extraordinarily active and thus also to enable
more patients with GIST to receive the drug
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sooner in several countries. GIST had been deﬁned as a separate
entity just a few years earlier; these tumors were differentiated from
mesenchymal neoplasms only during the 1990s and recognized as
being marked by a characteristic driving oncogene mutation.6,7
Imatinib was one of the ﬁrst molecularly targeted drugs available in
medical oncology.8
A total of 946 patients were entered onto this trial from 10
countries and two continents over approximately 1 year, whereas
the US trial enrolled 746 patients over the same interval. Although
it was already known that chemotherapy was largely inactive in
GIST,9 a signiﬁcant added value of this trial was that clinicians
worldwide had the formidable opportunity to learn new pat-
terns of tumor response, the occurrence of secondary resistance,
the potential of surgery for responding or progressing disease,
and so forth. Hundreds of patients received imatinib before
its approval by regulatory agencies, beginning in 2002.10 With
a long follow-up, it is logical to use these trials to look at the
long-term impact of imatinib in advanced GIST. The ﬁrst an-
alyses of the two European-Australian and US trials were
published in 2004 and 2008, respectively.4,5 With a median
follow-up in excess of 10 years, we report here on the updated
analysis of our trial, coordinated by the European Organisation
for Research and Treatment of Cancer Soft Tissue and Bone
Sarcoma Group and carried out on an intergroup basis with the
Italian Sarcoma Group and the Australasian Gastrointestinal
Trials Group.
PATIENTS AND METHODS
Study Design and Participants
This randomized, open-label, phase III study was open for ac-
crual between February 2001 and February 2002 in 56 centers from 13
countries in Europe and Australia, New Zealand, and Singapore.
Details on the study design have been published.4 Main eligibility
criteria included histologically proven advanced or metastatic GIST
characterized by c-KIT expression. Patients were not required to have
measurable disease. Previous chemotherapy was accepted but had to
be discontinued for more than 4 weeks before study entry. Other
criteria included age 18 years or older, WHO performance status less
than 4, absolute neutrophil count greater than 1.5 3 109/L, platelet
count greater than 1003 109/L, serum creatinine up to 1.53 the upper
limit of normal, and total bilirubin less than 1.53 the upper limit of
normal. Genomic DNA was not foreseen as per protocol but was
carried out on a subgroup of patients. Details have been published
separately.4 Institutional review boards approved the study protocol
according to applicable laws in all participating countries. All patients
gave written informed consent.
Eligible patients were randomly assigned centrally at the Euro-
pean Organisation for Research and Treatment of Cancer headquar-
ters, via Internet or phone, to receive imatinib 400 mg either once
a day or twice a day (800-mg daily dose). A minimization technique
was used, stratiﬁed by hospital, measurability of disease (measurable v
nonmeasurable), and performance status (0 to 2 v 3). Treatment al-
location was not masked.
The study drug was taken orally once a day or twice a day (depending
on the allocated treatment arm), directly after a meal. Dose modiﬁcations
for adverse events were done according to the protocol. After dose re-
duction, re-escalation was not allowed. However, in case of disease pro-
gression in a patient allocated to 400 mg once daily, the patient was allowed
to cross over to 400 mg twice daily, irrespective of the dose the patient was
taking at the time of progression. Clinical assessments of safety, including
medical history and physical examination, and laboratory assessments
were done at baseline, every week during the ﬁrst 2 months, every month
between months 3 and 6, and every 3 months thereafter. Computed to-
mography scans were performed after 2, 4, and 6 months and every
3 months thereafter until disease progression. Treatment was continued
until disease progression, unacceptable toxic effects (grade 3 or 4 adverse
events that could not be resolved by comedication or dose reduction), or
patient refusal. All patients were observed for survival (until death from
any cause or withdrawal of consent).
In the subset of patients tested for mutations, KITexons 9, 11, 13, and
17 were examined, and if any of these were detected, PDGFRA exons 12
and 18 were explored. If there were no mutations to these exons, patients
were coded as wild type.11
Outcomes
The primary end point was progression-free survival (PFS), which
was measured from the date of random assignment to the date of
documented progression or death, whatever the cause. Patients who were
alive and progression free at the last follow-up were censored. Secondary
end points included overall survival (OS), response, safety, and quality of
life. OS was measured from the date of random assignment to the date of
death, whatever the cause. Patients alive at the time of the analysis were
censored at the date of last follow-up. Response was evaluated according to
Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0.12 Best
response achieved from the entire period of protocol treatment (including
after crossover from 400 mg once daily to twice daily) is reported. The
response rate (RR) represents the proportion of patients achieving
a complete and/or partial response.
For patients crossing over upon progression to 400 mg twice
daily, PFS after crossover was determined from date of crossover to
date of progression or death. In these patients, the growth modulation
index (GMI) was estimated as the ratio of PFS after crossover to PFS
before crossover (ie, PFS after crossover/PFS before crossover). A GMI
greater than 1.33 has been proposed as an indication of an active next-
line treatment.13
Statistical Analysis
The time-to-event end points of OS and PFS were estimated using
the Kaplan-Meier method. The difference between the treatment arms is
reported in terms of the estimated hazard ratio (HR) and corresponding
CI and compared using a two-sided log-rank test. Comparison of RR
between the treatment groups was done using a x2 test. Prognostic factors
among baseline covariates were identiﬁed with univariable log-rank tests
and multivariable Cox regression using backward selection for PFS and
OS and with univariable x2 tests and multivariable logistic regression
incorporating backward selection for RR.
Patients randomly assigned
(N = 946)
Allocated to 400 mg of
  imatinib once a day 
Did not start treatment
Received treatment
Ineligible
(n = 473)
(n = 1)
(n = 472)
(n = 9)
Allocated to 400 mg of
  imatinib twice a day (n = 473)
Did not start treatment
Received treatment
Ineligible
(n = 1)
(n = 472)
(n = 9)
Experienced 
  progression
Died
Still alive
Still on treatment
(n = 417)
(n = 360)
(n = 82)
(n = 43)
Experienced
  progression
Died
Still alive
Still on treatment
(n = 405)
(n = 95)
(n = 339)
(n = 52)
Fig 1. CONSORT diagram.
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Logistic regression analyses, adjusting for censoring before the con-
sidered cutoffs, were performed to investigate the association between
baseline characteristics (including age, performance status, sex, prior surgery,
prior radiotherapy, prior chemotherapy, site ofmetastases, and time between
diagnosis and random assignment) and the probability of remaining
progression free beyond 10 years and the probability of surviving beyond
10 years. This was done using the pseudo-value regression technique.14,15
All tests were performed with a signiﬁcance level of P = .05 in the
intent-to-treat population. This analysis is based on all clinical data re-
ceived before the clinical cutoff date May 27, 2013.
Table 1. Baseline Characteristics and Best Overall Response to Treatment
Characteristic and Response
No. of Patients (%)
Treatment
Total
(N = 946)
400 mg/d
(n = 473)
800 mg/d
(n = 473)
Age, years
, 40 38 (8.0) 34 (7.2) 72 (7.6)
40-50 87 (18.4) 89 (18.8) 176 (18.6)
50-60 122 (25.8) 106 (22.4) 228 (24.1)
60-70 138 (29.2) 144 (30.4) 282 (29.8)
. 70 88 (18.6) 100 (21.1) 188 (19.9)
Median 60 61 60
Interquartile range 49-67 50-69 49-68
WHO performance status
0 217 (45.9) 219 (46.3) 436 (46.1)
1 191 (40.4) 192 (40.6) 383 (40.5)
2 48 (10.1) 44 (9.3) 92 (9.7)
3 17 (3.6) 18 (3.8) 35 (3.7)
Sex
Male 283 (59.8) 290 (61.3) 573 (60.6)
Female 190 (40.2) 183 (38.7) 373 (39.4)
Time since primary diagnosis, months
, 12 247 (52.2) 246 (52.0) 493 (52.1)
12-24 83 (17.5) 74 (15.6) 157 (16.6)
. 24 143 (30.2) 153 (32.3) 296 (31.3)
Prior treatment
Surgery 410 (86.7) 392 (82.9) 802 (84.8)
Radiotherapy 26 (5.5) 37 (7.8) 63 (6.7)
Chemotherapy 156 (33.0) 155 (32.8) 311 (32.9)
Site of origin
Abdominal 58 (12.3) 72 (15.2) 130 (13.7)
Gastric 161 (34.0) 158 (33.4) 319 (33.7)
Small bowel 124 (26.2) 114 (24.1) 238 (25.2)
Other GI 120 (25.4) 119 (25.2) 239 (25.3)
Other 10 (2.1) 10 (2.1) 20 (2.1)
Site of active disease
Primary tumor 150 (31.7) 168 (35.5) 318 (33.6)
Liver 325 (68.7) 344 (72.7) 669 (70.7)
Lymph node 49 (10.4) 66 (14.0) 115 (12.2)
Lung 41 (8.7) 40 (8.5) 81 (8.6)
Bone 7 (1.5) 12 (2.5) 19 (2.0)
Skin 7 (1.5) 4 (0.8) 11 (1.2)
Brain 1 (0.2) 0 (0.0) 1 (0.1)
KIT mutation present
Exon 11 118 (24.9) 130 (27.5) 248 (26.2)
Exon 9 28 (5.9) 34 (7.2) 62 (6.6)
Wild type 50 (10.6) 33 (7.0) 83 (8.8)
Other 10 (2.1) 13 (2.8) 23 (2.4)
Unknown 267 (56.4) 263 (55.6) 530 (56.0)
Baseline diameter largest lesion, mm
Median 80.0 80.0 80.0
Range 10.0-800.0 10.0-370.0 10.0-800.0
Q1-Q3 50.0-120.0 49.0-120.0 50.0-120.0
Best overall response to treatment
CR 33 (7.0) 32 (6.8) 65 (6.9)
PR 208 (44.0) 236 (49.9) 444 (46.9)
SD 160 (33.8) 141 (29.8) 301 (31.8)
PD 49 (10.4) 40 (8.5) 89 (9.4)
Early death 7 (1.4) 11 (2.3) 18 (1.9)
Unevaluable 16 (3.4) 13 (2.7) 29 (3.1)
Abbreviations: CR, complete response; PD, progressive disease; PR, partial response; Q, quartile; SD, stable disease.
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RESULTS
In this study, 946 patients were randomly assigned to receive either
imatinib 400 mg once daily (n = 473) or imatinib 400 mg twice
daily (800 mg; n = 473). As summarized in Figure 1, 18 patients
were ineligible for the study; six of these patients had another type
of cancer, four had ineligible concomitant disease, and eight were
ineligible for miscellaneous reasons. At the time of this analysis, the
median follow-up time was 10.9 years (interquartile range, 8.1 to
11.3 years). Details of patient baseline characteristics have been
reported previously.4 Table 1 lists the most important clinical
features by treatment arm. Thirty-three patients had non-
measurable (but still visible) disease.
At the time of the analysis, 95 patients were still on protocol
treatment. The major reason for protocol discontinuation was
disease progression (67.6% of patients in both arms), followed by
patient refusal (7.0% in 400-mg arm v 4.5% in 800-mg arm) and
toxicity (5.3% in 400-mg arm v 5.9% in 800-mg arm). Among the
95 patients still on protocol treatment, median time on treatment
was 9.6 years (interquartile range, 6.4 to 11.1 years). One hundred
seventy-ﬁve patients underwent surgery while on study (35 and 96
patients underwent excision of residual responding disease and
progressive disease, respectively).
No signiﬁcant difference was observed between the two
treatment arms in terms of PFS (HR for 400 mg v 800 mg, 0.91;
95% CI, 0.79 to 1.04; P = .18; Fig 2A) or OS (HR, 0.93; 95% CI,
0.80 to 1.07; P = .31; Fig 2B). Eight hundred twenty-two patients
(417 and 405 patients in the 400- and 800-mg arms, respectively)
were reported to have experienced progression on treatment. Six
hundred ninety-nine patients (360 and 339 patients in the 400- and
800-mg arms, respectively) were reported to have died on study,
including 596 patients (310 v 286 in 400- and 800-mg arm, re-
spectively) as a result of progressive disease and/or toxicity, 14 as
a result of cardiovascular disease, 13 as a result of infection un-
related to imatinib, 13 as a result of intercurrent death, two as
a result of pulmonary complications, and 36 as a result of other
reasons. For 25 patients, the cause of death is unknown. The
estimated 10-year PFS rates were 9.5% and 9.2% for the 400- and
800-mg arms, respectively, and the estimated 10-year OS rates were
19.4% and 21.5%, respectively. Sixty-ﬁve patients (33 v 32 patients
in the 400- and 800-mg arms, respectively) achieved a complete
response, and 444 patients (208 v 236 patients, respectively)
achieved a partial response (Table 1). There was no signiﬁcant
difference in RR between the two arms (P = .08).
Prognostic Factors
Appendix Table A1 (online only) reports on the univariable
and multivariable prognostic factor analysis for PFS. Performance
status, prior chemotherapy, diameter of longest lesion, and KIT
mutation were found to be statistically signiﬁcantly associated with
PFS in univariable analyses as well as in a multivariable Cox re-
gression model. Note that in the latter model, unknown KIT
mutation status was taken into account as a separate category to
reduce loss of patient information in the model estimation. In
addition, KITmutation status was conﬁrmed to be predictive for
PFS (P = .01; Fig 3A), whereby patients with a KITexon 9 mutation
signiﬁcantly beneﬁt from treatment with imatinib 800 mg daily
(HR, 0.40; 95% CI, 0.22 to 0.72).
Appendix Table A2 (online only) summarizes the results of
the prognostic factor analysis for OS. In the univariable ana-
lyses, age, performance status, prior surgery, prior radiotherapy,
prior chemotherapy, diameter of longest lesion, and KIT mu-
tation were found to be signiﬁcantly associated with survival.
Prior surgery and radiotherapy did not remain statistically
signiﬁcant prognostic factors in a multivariable model adjusting
for the other baseline covariates, whereas sex became signiﬁ-
cant. KITmutation status was not found to be prognostic for OS
(P = .23; Fig 3B), but patients with a KIT exon 9 mutation had
a signiﬁcantly better survival with imatinib 800 mg daily (HR,
0.54; 95% CI, 0.31 to 0.96).
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Fig 2. Kaplan-Meier plots of (A) progression-free survival (PFS) and (B) overall survival (OS).
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Univariable prognostic factor analyses for RR only identiﬁed
KITmutation status as signiﬁcant (P , .01), where patients with
aKITexon 11mutation had a signiﬁcantly higher odds of achieving
a response compared with patients with KIT exon 9 mutations
(odds ratio [OR], 4.35; 95% CI, 2.44 to 7.96), wild-type KIT (OR,
11.1; 95% CI, 5.88 to 20), or other mutation (OR, 3.13; 95% CI,
1.31 to 7.69).
Special Patient Subgroups
At the time of analysis, 59 patients (6.2%) had been alive and
progression free for $ 10 years, whereas 69 patients (7.3%) were
censored before 10 years. The baseline characteristics of these 59
patients are listed in Table 2. Table 2 also lists the results of the
multivariable prognostic factor analysis, performed to assess the
impact of the different baseline covariates on the probability of
remaining progression free for at least 10 years, while adjusting for
censoring before 10 years. Only the size of the largest lesion was
identiﬁed as being signiﬁcantly prognostic. In fact, the probability
of remaining progression free for at least 10 years decreases as long
as the lesion size increases.
Table 2 lists the baseline characteristics of the 120 patients
(12.7%)whowere still alive after 10 years of follow-up; 144 patients are
considered censored before 10 years. The corresponding multivariable
analysis, adjusting for censoring before 10 years, showed that age (, 60
years), performance status (0 v$ 1), size of the largest lesion (smaller),
and KITmutation (exon 11) were signiﬁcant prognostic factors for the
probability of surviving beyond 10 years.
Crossover
Of 417 patients in the 400-mg arm who experienced pro-
gression, 196 patients crossed over after progression according to
protocol to the 800-mg arm, 103 continued imatinib off pro-
tocol, and 116 stopped imatinib entirely; for two patients, no
follow-up data were available. Of the 196 patients who crossed
No. of Events/No. of Patients
800 mg/d  400 mg/d
Statistics
O – E Variance
HR and 95% CI
800 mg/d 400 mg/d HR (95% CI)
Q = 10.93 (df = 3), P = .01, I2 = 72.6% (95% CI, 22.4% to 90.3%)
800 mg/d
Better
400 mg/d
Better
Heterogeneity
0.25 0.5 1.0 2.0 4.0
Other 13/13 10/10 –0.6 5.3 0.90 (0.38 to 2.11)
Total
 191/210
(91%)
 185/206
(89.8%)
–6.9 86.7 0.92 (0.75 to 1.14)
Wild type 32/33 44/50  5.7 16.5 1.41 (0.87 to 2.28)
Exon 9 32/34 28/28 –10.3 11.3 0.40 (0.22 to 0.72)
KIT mutation
Exon 11 114/130 103/118 –1.7 53.6 0.97 (0.74 to 1.27)
A
No. of Events/No. of Patients
800 mg/d 400 mg/d
Statistics
O – E Variance
HR and 95% CI
800 mg/d 400 mg/d HR (95% CI)
800 mg/d
Better
400 mg/d
Better
Q = 4.34 (df = 3), P = .23, I2 = 30.9% (95% CI, 0% to 75.1%)
Heterogeneity
Total
 160/210
(76.2%)
 164/206
(79.6%)
 –9.7 77.2
KIT mutation
Exon 11 89/130 89/118 –5.4 44.2
0.88 (0.71 to 1.10)
0.89 (0.66 to 1.19)
0.25 0.5 1.0 2.0 4.0
Exon 9 29/34 26/28 –7.2 11.7 0.54 (0.31 to 0.96)
Wild type 29/33 40/50  1.7 16 1.11 (0.68 to 1.81)
Other 13/13 9/10 1.2 5.2 1.27 (0.54 to 3.01)
B
Fig 3. Forest plots for the interaction effect of KITmutation status on treatment in predicting (A) progression-free survival and (B) overall survival. E, expected; HR, hazard
ratio; O, observed.
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over according to protocol, discontinuation has been docu-
mented for 194 patients, and median time on imatinib after
crossover was estimated to be 3.6 months (95% CI, 2.6 to
4.7 months). One year after crossover, 17.4% of patients were
estimated to still be on protocol treatment. PFS after crossover
for these patients is compared with time to ﬁrst progression in
the same patient population in Figure 4. Thirty-four patients
achieved a GMI greater than 1.33, whereas 145 patients had
a GMI # 1.
DISCUSSION
We report here a large, randomized, clinical trial performed in 946
patients with advanced GIST treated with imatinib by a commu-
nity of researchers from 58 institutions on two continents at the
beginning of their learning curve regarding this new molecularly
targeted agent. With a median follow-up of more than 10 years,
slightly less than 10% and 15% of patients became long-term
Table 2. Baseline Characteristics of Special Patient Subsets
Characteristic
Patients Progression Free at 10 Years (n = 59) 10-Year Survivors (n = 120)
Total
Patients
(N = 946),
No. (%)
No. of Patients
(%)
Reduced Multivariable Model
(backward selection)
No. of Patients
(%)
Reduced Multivariable Model
(backward selection)
Odds Ratio
(95% CI) P
Odds Ratio
(95% CI) P
Treatment group, mg
400 30 (50.8) 61 (50.8) 473 (50.0)
800 29 (49.2) 59 (49.2) 473 (50.0)
Age group, years .03 (df = 3)
, 40 4 (6.8) 13 (10.8) 1.00 72 (7.6)
40-50 11 (18.6) 23 (19.2) 0.57 (0.29 to 1.13) 176 (18.6)
50-60 19 (32.2) 40 (33.3) 0.82 (0.45 to 1.52) 228 (24.1)
$ 60 25 (42.4) 44 (36.7) 0.48 (0.26 to 0.87) 470 (49.7)
Performance status , .01 (df = 2)
0 39 (66.1) 80 (66.7) 1.00 436 (46.1)
1 15 (25.4) 34 (28.3) 0.52 (0.35 to 0.79) 383 (40.5)
$ 2 5 (8.5) 6 (5.0) 0.31 (0.10 to 0.95) 127 (13.4)
Sex
Male 32 (54.2) 68 (56.7) 573 (60.6)
Female 27 (45.8) 52 (43.3) 373 (39.4)
Time since primary diagnosis, months
, 12 30 (50.8) 59 (49.2) 493 (52.1)
12-24 11 (18.6) 21 (17.5) 157 (16.6)
. 24 18 (30.5) 40 (33.3) 296 (31.3)
KIT mutation .01 (df = 2)
Exon 11 17 (28.8) 38 (31.7) 1.00 248 (26.2)
Non–exon 11 5 (5.5) 10 (8.3) 0.24 (0.09 to 0.61) 168 (17.8)
Unknown 37 (62.7) 72 (60.0) 0.84 (0.56 to 1.25) 530 (56.0)
Prior treatment
Surgery 52 (88.1) 104 (86.7) 802 (84.8)
Radiotherapy 3 (5.1) 4 (3.3) 63 (6.7)
Chemotherapy 15 (25.4) 35 (29.2) 311 (32.9)
Site of origin
Abdominal 8 (13.6) 15 (12.5) 130 (13.7)
Gastric 21 (35.6) 40 (33.3) 319 (33.7)
Small bowel 15 (25.4) 30 (25.0) 238 (25.2)
Other GI 14 (23.7) 33 (27.5) 239 (25.3)
Other 1 (1.7) 2 (1.7) 20 (2.1)
Site of metastases (noncumulative
overview)
Primary tumor 21 (35.6) 39 (32.5) 318 (33.6)
Lymph node 4 (6.8) 11 (9.2) 115 (12.2)
Lung 3 (5.1) 4 (3.3) 81 (8.6)
Liver 44 (74.6) 83 (69.2) 669 (70.7)
Bone 0 (0.0) 0 (0.0) 19 (2.0)
Brain 0 (0.0) 0 (0.0) 1 (0.1)
Skin 0 (0.0) 0 (0.0) 11 (1.2)
Ascites 2 (3.4) 3 (2.5) 66 (7.0)
Pleural effusion 5 (8.5) 6 (5.0) 30 (3.2)
Baseline diameter of largest lesion, mm .01 (df = 1) , .01 (df = 1)
Median 59.0 0.90* (0.83 to 0.97) 57.0 0.89* (0.83 to 0.95) 80.0
Range 15.0-240.0 10.0-260.0 10.0-800.0
Quartile 1-quartile 3 42.0-100.0 38.0-100.0 50.0-120.0
Unknown 4 (6.8) 6 (5.0) 30 (3.2)
*Per 10-mm increase.
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progression-free and long-term overall survivors, respectively.
Median OS was 3.9 years, and median PFS was 1.9 years. An
imatinib-sensitive mutational status and a low initial tumor
burden were favorable prognostic factors, being related to
a good tumor response and a good progression-free interval,
respectively.11,16
With regard to the formal objective of this trial, which was
comparing 400 v 800 mg of imatinib, data from the two twin trials
point to a lack of any difference. Unfortunately, mutational analysis
could not be foreseen by the protocol, given the time when the
study was conceived. Thus, only a subset of patients were geno-
typed. The beneﬁt in PFS for exon 9–mutated patients starting at
800 mg was already reported in a meta-analysis of the two twin
trials.17 Likewise, we had already reported the beneﬁt of dose
escalation to 800 mg at the time of progression.18 In principle,
open issues are which patient subgroups may beneﬁt from dose
escalation on progression and whether a policy of planned dose
escalation on progression is actually inferior to starting at 800 mg
for patients with exon 9 mutations. Starting at 800 mg in patients
with exon 9–mutated GIST is recommended by some clinical
practice guidelines, although there are regulatory barriers in some
countries. Unfortunately, a formal comparison between starting at
400 mg, with subsequent escalation, and starting at 800 mg was
unfeasible given the data available in this trial, because dose es-
calation was not carried out regularly and a selection bias would
ﬂaw any comparison.
The greater than 900 patients who were entered onto this trial
may be viewed as having inherently unfavorable prognostic factors,
because they were selected from patients waiting for any treatment
at the time. Thus, their tumor burden was substantial, on average,
and likely larger than that of average patients with advanced GIST
who are starting imatinib today. Indeed, this study and others
showed that tumor burden is a prognostic factor.16 In addition,
centers were at the beginning of their learning curve. Finally, GISTs
are rare cancers that had been deﬁned just a few years before this
study.6,19 All of these factors add to the value of these long-term
results, which basically conﬁrm the sharp improvement in PFS and
OS that occurred in the past 15 years for patients with metastatic
GIST. Indeed, the prognosis of patients with advanced GIST
starting imatinib today might be better overall. However, sec-
ondary resistance has been proven to be a major limiting factor of
molecularly targeted therapies in advanced solid cancers. In fact, in
this trial, only 10% of patients were progression free at 10 years.
Indeed, the presence of a distinct, albeit limited, subset of
long-term survivors, and even progression-free survivors, is of
high interest clinically and biologically. It is still to be de-
termined whether a subset of patients with metastatic GIST are
liable to be cured by a highly active molecularly targeted agent
such as imatinib. Many of these patients are continuing their
treatment, because stopping therapy was demonstrated to re-
sult in tumor progression in most patients, although data are
lacking in the subgroup of long-term survivors. A minority of
patients in this study underwent surgery of residual disease,
including responsive residual disease, but no conclusion can be
drawn as a result of the small number of patients and the highly
variable selection criteria for surgery, which was clearly un-
planned as per protocol. The effect of surgery is the subject of
a separate analysis.
Unfortunately, no major convincing clinical prognostic fac-
tors seem to predict for long-term survivorship, let alone
progression-free survivorship. From this and other studies, we have
learned that in advanced GIST the almost only predictive factor for
response to imatinib is genotype. The main predictive factor for
duration of response is tumor burden. No other relevant predictive
or prognostic factors seem to exist, according to the best data
available today, for long-term survivorship, assuming that good PS
and the lack of previous chemotherapy are surrogates for disease
burden. In other words, it is still to be determined whether the
presence of a subgroup of long-term progression-free survivors is
just the expression of the stochastic mechanisms of tumor re-
sistance, being the tail of a random Gaussian distribution, or is the
product of distinct features. Given the nature of this trial, we were
unable to carry out any genomic proﬁling, immune character-
ization, and the like. Efforts to this end are ongoing in small series;
however, the limited number of patients with GIST and their
dispersion are obvious limiting factors. We hope that collaborative
efforts on a global scale may be commenced. At this time, to improve
GIST treatment, the priority is to try and prevent secondary re-
sistance to tyrosine kinase inhibitors, either through other agents or
by combinations or rotations of new or available agents, in the
adjuvant and advanced settings.
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Appendix
Table A1. Univariable and Multivariable Analysis of Prognostic Factors for Progression-Free Survival
Covariate
Univariable Analysis
Multivariable Model After
Backward Selection (N = 913)
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Treatment, mg .18 (df = 1)
400 1.00
800 0.91 (0.79 to 1.04)
Age, years .17 (df = 4)
, 40 1.00
40-50 1.07 (0.79 to 1.44)
50-60 1.08 (0.81 to 1.45)
60-70 0.98 (0.74 to 1.30)
. 70 1.26 (0.93 to 1.69)
Performance status , .01 (df = 3) , .01 (df = 3)
0 1.00 1.00
1 1.22 (1.05 to 1.41) 1.17 (1.00 to 1.36)
2 1.74 (1.38 to 2.20) 1.52 (1.19 to 1.95)
3 2.45 (1.73 to 3.47) 2.16 (1.51 to 3.10)
Sex .38 (df = 1)
Male 1.00
Female 0.94 (0.82 to 1.08)
Time between diagnosis and registration, months .69 (df = 2)
, 12 1.00
12-24 0.95 (0.79 to 1.16)
. 24 0.94 (0.80 to 1.09)
Prior surgery .11 (df = 1)
No 1.00
Yes 0.86 (0.71 to 1.04)
Prior radiotherapy .10 (df = 1)
No 1.00
Yes 1.26 (0.96 to 1.66)
Prior chemotherapy .01 (df = 1) .05 (df = 1)
No 1.00 1.00
Yes 1.20 (1.04 to 1.38) 1.16 (1.00 to 1.35)
Primary site .52 (df = 4)
Abdominal 1.00
Small bowel 0.87 (0.69 to 1.08)
Gastric 0.98 (0.78 to 1.23)
Other GI 0.96 (0.76 to 1.21)
Other 1.11 (0.68 to 1.83)
Diameter of longest lesion , .01 (df = 1) , .01
Per 10-mm increase 1.03 (1.02 to 1.04) 1.02 (1.01 to 1.04)
KIT mutation , .01 (df = 3) , .01 (df = 4)
Exon 11 1.00 1.00
Exon 9 1.94 (1.45 to 2.58) 1.78 (1.32 to 2.40)
Wild type 1.90 (1.46 to 2.47) 2.10 (1.60 to 2.76)
Other 2.93 (1.89 to 4.54) 2.90 (1.84 to 4.57)
Unknown 1.01 (0.86 to 1.19)
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Table A2. Univariable and Multivariable Analysis of Prognostic Factors for Overall Survival
Covariate
Univariable Analysis
Multivariable Model After
Backward Selection (N = 913)
Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P
Treatment, mg .31 (df = 1)
400 1.00
800 0.93 (0.80 to 1.07)
Age, years , .01 (df = 4) , .01 (df = 4)
, 40 1.00 1.00
40-50 1.35 (0.95 to 1.91) 1.13 (0.79 to 1.61)
50-60 1.50 (1.07 to 2.11) 1.45 (1.03 to 2.04)
60-70 1.40 (1.00 to 1.95) 1.30 (0.93 to 1.81)
. 70 2.19 (1.56 to 3.08) 2.02 (1.42 to 2.87)
Performance status , .01 (df = 3) , .01 (df = 3)
0 1.00 1.00
1 1.59 (1.35 to 1.87) 1.48 (1.25 to 1.75)
2 2.38 (1.85 to 3.05) 1.84 (1.42 to 2.40)
3 3.54 (2.46 to 5.09) 3.04 (2.09 to 4.42)
Sex .25 (df = 1) .02 (df = 1)
Male 1.00 1.00
Female 0.91 (0.79 to 1.06) 0.83 (0.70 to 0.97)
Time between diagnosis and registration, months .67 (df = 2)
, 12 1.00
12-24 0.95 (0.77 to 1.17)
. 24 0.93 (0.79 to 1.10)
Prior surgery .03 (df = 1)
No 1.00
Yes 0.80 (0.65 to 0.98)
Prior radiotherapy .02 (df = 1)
No 1.00
Yes 1.41 (1.05 to 1.89)
Prior chemotherapy , .01 (df = 1) , .01 (df = 1)
No 1.00 1.00
Yes 1.29 (1.10 to 1.50) 1.31 (1.11 to 1.55)
Primary site .68 (df = 4)
Abdominal 1
Small bowel 0.99 (0.77 to 1.26)
Gastric 0.89 (0.70 to 1.12)
Other GI 0.89 (0.70 to 1.15)
Other 1.09 (0.64 to 1.84)
Diameter of longest lesion , .01 (df = 1) , .01 (df = 1)
Per 10-mm increase 1.04 (1.03 to 1.05) 1.03 (1.02 to 1.04)
KIT mutation , .01 (df = 3) , .01 (df = 4)
Exon 11 1 1.00
Exon 9 2.09 (1.54 to 2.83) 1.87 (1.36 to 2.57)
Wild type 1.82 (1.37 to 2.40) 2.10 (1.57 to 2.81)
Other 2.15 (1.38 to 3.36) 2.68 (1.68 to 4.28)
Unknown 1.09 (0.90 to 1.31)
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